enVVeno Medical Corporation (NASDAQ:NVNO – Get Rating) shares traded down 2.8% during mid-day trading on Friday . The company traded as low as $3.80 and last traded at $3.82. 18,198 shares were traded during trading, a decline of 29% from the average session volume of 25,486 shares. The stock had previously closed at $3.93.
enVVeno Medical Stock Performance
The business’s 50-day simple moving average is $4.54 and its 200-day simple moving average is $5.18.
Hedge Funds Weigh In On enVVeno Medical
An institutional investor recently bought a new position in enVVeno Medical stock. Dimensional Fund Advisors LP purchased a new position in shares of enVVeno Medical Corporation (NASDAQ:NVNO – Get Rating) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,489 shares of the company’s stock, valued at approximately $135,000. Dimensional Fund Advisors LP owned about 0.23% of enVVeno Medical at the end of the most recent quarter. 23.05% of the stock is owned by hedge funds and other institutional investors.
enVVeno Medical Company Profile
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
- Get a free copy of the StockNews.com research report on enVVeno Medical (NVNO)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.